Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 118-123 , May 2007

CD40 and Its Ligand in Atherosclerosis

References 

  1. Ahonen C, Manning E, Erickson LD, et al. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat Immunol. 2002;3:451–456
  2. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247–252
  3. Anolik J, Looney RJ, Bottaro A, et al. Down-regulation of CD20 on B cells upon CD40 activation. Eur J Immunol. 2003;33:2398–2409
  4. Arron JR, Pewzner-Jung Y, Walsh MC, et al. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp Med. 2002;196:923–934
  5. Bavendiek U, Libby P, Kilbride M, et al. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002;277:25032–25039
  6. Bavendiek U, Zirlik A, LaClair S, et al. Atherogenesis in mice does not require CD40 ligand from bone marrow-derived cells. Arterioscler Thromb Vasc Biol. 2005;25:1244–1249
  7. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719–727
  8. Chen Y, Chen J, Xiong Y, et al. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun. 2006;345:106–117
  9. Davis JC, Totoritis MC, Rosenberg J, et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:95–101
  10. Durie FH, Fava RA, Foy TM, et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 1993;261:1328–1330
  11. Foy TM, Aruffo A, Bajorath J, et al. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 1996;14:591–617
  12. Grewal IS, Foellmer HG, Grewal KD, et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 1996;273:1864–1867
  13. Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci U S A. 2005;102:2874–2879
  14. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–1111
  15. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–594
  16. Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem. 2000;275:15392–15398
  17. Ishida TK, Tojo T, Aoki T, et al. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci U S A. 1996;93:9437–9442
  18. Kalunian KC, Davis JC, Merrill JT, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251–3258
  19. Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood. 2004;103:1229–1236
  20. Li H, Nord EP. Functional caveolae are a prerequisite for CD40 signaling in human renal proximal tubule cells. Am J Physiol Renal Physiol. 2004;286:F711–F719
  21. Lutgens E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A. 2000;97:7464–7469
  22. Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med. 2002;12:27–32
  23. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313–1316
  24. Mach F, Schonbeck U, Bonnefoy JY, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396–399
  25. Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis?. Atherosclerosis. 1998;137(Suppl):S89–S95
  26. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200–203
  27. Malapati S, Pierce SK. The influence of CD40 on the association of the B cell antigen receptor with lipid rafts in mature and immature cells. Eur J Immunol. 2001;31:3789–3797
  28. Manning E, Pullen SS, Souza DJ, et al. Cellular responses to murine CD40 in a mouse B cell line may be TRAF dependent or independent. Eur J Immunol. 2002;32:39–49
  29. McPherson PS, Kay BK, Hussain NK. Signaling on the endocytic pathway. Traffic. 2001;2:375–384
  30. Mukundan L, Bishop GA, Head KZ, et al. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol. 2005;174:1081–1090
  31. Mukundan L,, Milhorn DM, Matta B, Suttles J. CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway. Cell Signal. 2004;16:375–384
  32. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse?. Arterioscler Thromb Vasc Biol. 2006;26:2421–2432
  33. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092–1103
  34. Schonbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A. 2000;97:7458–7463
  35. Smook ML, Heeringa P, Damoiseaux JG, et al. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis. 2005;183:275–282
  36. Suttles J, Milhorn DM, Miller RW, et al. CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action. J Biol Chem. 1999;274:5835–5842
  37. Urbich C, Mallat Z, Tedgui A, et al. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest. 2001;108:1451–1458
  38. Vidalain PO, Azocar O, Servet-Delprat C, et al. CD40 signaling in human dendritic cells is initiated within membrane rafts. EMBO J. 2000;19:3304–3313
  39. Wagner AH, Guldenzoph B, Lienenluke B, Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol. 2004;24:715–720
  40. Xie P, Hostager BS, Munroe ME, et al. Cooperation between TNF receptor-associated factors 1 and 2 in CD40 signaling. J Immunol. 2006;176:5388–5400
  41. Yellin MJ, Sippel K, Inghirami G, et al. CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J Immunol. 1994;152:598–608
  42. Zapata JM. TNF-receptor-associated factors as targets for drug development. Expert Opin Ther Targets. 2003;7:411–425

PII: S1050-1738(07)00048-5

doi: 10.1016/j.tcm.2007.02.004

Trends in Cardiovascular Medicine
Volume 17, Issue 4 , Pages 118-123 , May 2007

Article Tools

* Image Usage & Resolution